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Received May 5, 2014; accepted October 21, 2014AbstractCorneal neovascularization (NV), the excessive ingrowth of blood vessels from conjunctiva into the cornea, is a common sequela of disease
insult that can lead to visual impairment. Clinically, topical steroid, argon laser photocoagulation, and subconjunctival injection of bevacizumab
have been used to treat corneal NV. Sometimes, the therapies are ineffective, especially when the vessels are large. Large vessels are difficult to
occlude and easily recanalized. Scientists and physicians are now dedicated to overcoming this problem. In this article, we briefly introduce the
pathogenesis of corneal NV, and then highlight the existing animal models used in corneal NV researchdthe alkali-induced model and the
suture-induced model. Most of all, we review the potential therapeutic targets (i.e., vascular endothelial growth factor and platelet-derived
growth factor) and their corresponding inhibitors, as well as the immunosuppressants that have been discovered in recent years by corneal
NV studies.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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The cornea is the outermost part of the eye, constituting the
most important refractive structure of the visual system.
Avascularity and transparency of the cornea are vital to normal
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* Corresponding author. Dr. Yan-Ting Chen, Department of Ophthalmology,
Changhua Christian Hospital, 135, Nanhsiao Street, Changhua 500, Taiwan,
ROC.
E-mail address: ciloxan@gmail.com (Y.-T. Chen).
http://dx.doi.org/10.1016/j.jcma.2014.10.002
1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Asscan be divided into five parts: the epithelium, Bowman's layer,
stroma, Descemet’s membrane, and endothelium. The
epithelium is composed of five to seven layers of cells that are
continuous with the conjunctival epithelium. The epithelium is
responsible for maintaining the smoothness and integrity of
the anterior surface of the cornea. The stromal part is the
thickest part of the cornea. Its transparency depends on strictly
arranged collagen fibers and endothelial pumping function.
Endothelial cells are responsible for water and solute transport
between the corneal stroma and the aqueous humor, but are
unable to regenerate in humans.
In most tissues, blood and lymphatic vessels are needed to
supply oxygen and nutrients, drain extracellular fluid, andociation. All rights reserved.
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unique tissue without vascularization. The glucose diffusing
from the aqueous humor and oxygen diffusing through the tear
film meet the metabolite demand of the cornea, so it can
remain avascular in a healthy eye. In some diseased condi-
tions, pathologic corneal hemangiogenesis or lymphangio-
genesis occurs, which decreases corneal transparency.
Situations leading to corneal angiogenesis are mostly associ-
ated with hypoxia, infection, inflammation, and poor limbal
barrier function.1,2 Accordingly, patients with transplanted
cornea, infectious keratitis, ocular chemical or traumatic
injury, autoimmune diseases, and chronic contact lens wear
are at risk of developing corneal neovascularization (NV). We
summarize the etiologies of corneal NV in Table 1.1e3
Angiogenesis, the formation of new vessels from preex-
isting vascular structures, is different from physiological vas-
culogenesis. Vasculogenesis means the formation of new
blood vessels from bone marrow-derived angioblasts, which
mainly occurs during embryogenesis.4 Angiogenesis results
from an imbalance between angiogenic and antiangiogenic
factors.5 These factors promote the migration and proliferation
of vascular endothelial cells, finally forming a capillary tube as
a part of the wound-healing process.6,7
Corneal NV has three clinical patterns. The first one,
vascular pannus, results from ocular surface disease. The
second is stromal NV, which results from stromal keratitis or
alkaline injury. The third is deep NV overlying Descemet's
membrane, which can be observed in herpes or interstitial
keratitis.1,2,5,8,9 Mixed patterns are often seen clinically. Re-
searchers have been working on different strategies for the
anti-(lymph) angiogenic therapies of different patterns.
2. Animal models of corneal NV
In order to survey the pathogenesis of corneal hemangio-
genesis, lymphangiogenesis, and tissue responses to therapies,
scientists have developed some platforms to simulate these
conditions. Many different methods have been used to induce
corneal NV in animals. Among these, alkali burn and sutureTable 1
Causes of corneal neovascularization.
Categories Cause
Hypoxia Contact lens wearing
Infectious keratitis Viral
Fungal
Bacterial
Parasitic
Inflammatory disorder Mucous membrane pemphigoid
StevenseJohnson syndrome
Atopic conjunctivitis
Rosacea
Lyell's syndrome
Corneal graft rejection
Loss of limbal
barrier function
Limbal stem cell deficiency
Chemical burn, thermal burn, or other injury
Other disorders Ocular surface neoplasia (papilloma, and
conjunctival or corneal intraepithelial neoplasia)
Pterygiumplacement are the two animal models that are widely accepted.
In the alkali-induced model, corneal NV can be induced by a
paper disc soaked with 1N NaOH placed on the animal ocular
surface for 10 seconds. The paper disc is later removed, and
the ocular surface is washed with normal saline. In the suture-
induced model, corneal NV can be triggered by directly su-
turing two stitches with 10-0 nylon onto the temporal cornea.
In both models, corneal NV will appear and progressively
extend its occupying area within 2 weeks. Giacomini and
colleagues10 compared these two models in C57BL/6 mice
and FVB mice. They found that hemangiogenesis was similar
between these two models in C57BL/6 mice, and in the su-
tured models between C57BL/6 and FVB. Corneal lym-
phangiogenesis was more pronounced in the sutured group
than in the alkali burn group of C57BL/6 mice. More promi-
nent lymphatic vessels were noted in the FVB strain,
compared with both models in C57BL/6 mice. Thus, the su-
ture model may be more appropriate for the survey of corneal
lymphangiogenesis. Jia and coworkers11 compared the
genome-wide gene expression between suture- and alkali-
induced murine models by microarray assay. The results
pointed out that the overlapping upregulated genes were
associated with chemotaxis and immune response, whereas
downregulated genes were associated with oxidation reduction
and programmed cell death. In both models, vascular endo-
thelial growth factor (VEGF) was upregulated, while pigment
epithelium-derived factor (PEDF) remained stable.
Another frequently used method for the in vivo survey of
corneal NV is corneal micropocket assay, which needs to
create two adjacent micropockets on the animal cornea. VEGF
or basic fibroblast growth factor (bFGF) is implanted in one
micropocket, while the target antiangiogenic agent is
implanted in the other. The degree of corneal NV can be
measured using a slit-lamp stereomicroscope.
3. Potential targets of therapy
There are many potential targets for antiangiogenic
therapies. With new techniques to enhance or suppress these
targets, we can reduce corneal NV and maintain corneal
transparency. We depicted several important targets and
summarized their related therapies in
Table 2.19e33,36,38,42e46,48,49,54e57,60e62,66,67,71,73,74,77,78,80e873.1. Vascular endothelial growth factorVEGF is the most important target for antiangiogenic
therapies. The so-called VEGF family includes VEGF-A,
VEGF-B, VEGF-C, VEGF-D, and placental growth factor.12
VEGF-A can induce hemangiogenesis through VEGF recep-
tor (VEGFR)-2, whereas VEGF-C and VEGF-D can stimulate
lymphangiogenesis through VEGFR-2 and VEGFR-3,
respectively.13e16 Macrophages in corneal stroma can also
produce VEGF-A, VEGF-C, and VEGF-D after injury or
inflammation.17 Therapies that block VEGF may reduce
corneal hemangiogenesis and lymphangiogenesis through
regulating the signaling pathway of receptor tyrosine kinases,
Table 2
Corneal antiangiogenesis target therapies.a
Targets Methods Therapeutics
Vascular endothelial growth factor Anti-VEGF-A antibodies Bevacizumab19e27
Ranibizumab21,23,25,26,28e32
FD00633
Soluble or modified VEGF receptors Recombinant dimeric VEGFR-2-Fc36
sVEGFR-1 overexpression gene therapy42
sVEGFR-3 overexpression gene therapy38
VEGFR-1 morpholino43
Aflibercept/VEGF-Trap(R1R2)
44,45
VEGFR intraceptor gene therapy (Flt23k, Flt24k)46,48,49
VEGF-A aptamer Pegaptanib23,26
Pigment epithelium-derived factor PEDF direct effect PEDF54
PEDF-derived peptide55
PEDF gene therapy56,57
Platelet-derived growth factor PDGF receptor inhibitor AG 129660,61
Multitargeted receptor tyrosine kinase inhibitor Sunitinib62
Angiostatin Angiostatin direct effect Angiostatin pump66
Hypoxia-inducible factors shRNA for hypoxia-inducible factors HIF-1a shRNA gene therapy (HIF-1a RNAi-A)67
12-Hydroxyeicosatrienoic acid siRNA for cytochrome P450 mono-oxygenase CYP4B1 siRNA gene therapy71
Vascular adhesion protein VAP-1/SSAO inhibitor UeV00273
LJP120774
Decorin Decorin direct effect Decorin gene therapy77
Vasohibin-1 Vasohibin-1 directly effect Vasohibin-1 gene therapy78
Cannabinoid receptor CB1 CB1 antagonist Rimonabant80
CYP ¼ cytochrome P450 mono-oxygenase; HIF-1a ¼ hypoxia-inducible factor 1a; PDGF ¼ platelet-derived growth factor; PEDF ¼ pigment epithelium-derived
factor; SSAO ¼ semicarbazide-sensitive amine oxidase; sVEGFR ¼ soluble form of vascular endothelial growth factor receptor; VAP-1 ¼ vascular adhesive
protein-1; VEGF ¼ vascular endothelial growth factor; VEGFR ¼ vascular endothelial growth factor receptor.
a Other potential therapies: steroid (dexamethasone, prednisolone, fluorometholone), rapamycin, cyclosporine A, thalidomide analogue (CC-3052).81e87
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been developed to block the signaling pathway of VEGF-A,
for example, monoclonal anti-VEGF-A immunoglobulin or
fragment antigen-binding (Fab fragment), fusion protein,
aptamer, decoy or soluble VEGFR, and anti-VEGFR antago-
nist. These strategies will be discussed in more detail below.3.2. Anti-VEGF-A antibodiesMany anti-VEGF-A antibodies are now available in the
market and act as popular antiangiogenic therapies. Bev-
acizumab is a whole anti-VEGF-A immunoglobulin, widely
used in many retinal disorders such as choroidal NV, diabetic
retinopathy, and retinal vein occlusion by intravitreal in-
jections. Some researchers have also tried to use bevacizumab
in corneal NV. When bevacizumab was administrated in a
high-risk murine corneal transplantation model, it could
significantly reduce corneal NV and increase graft survival by
the subconjunctival route rather than by the topical route.19
Similar conclusions were also drawn by randomized clinical
trials on high-risk corneal transplantation in humans.20 The
effect of bevacizumab in suture- or burn-induced animal
models of corneal NV was also confirmed by the decrease in
the area of corneal NV after subconjunctival injections21e26 or
topical administration.22 With persistent topical administra-
tion, the therapeutic effect could even last longer than infre-
quent early-phase subconjunctival injections in a silver/
potassium nitrate cauterized model.21 However, when thetopical or subconjunctival administration of bevacizumab was
postponed 2 weeks after suture injury in an animal model, its
effect of reducing corneal NV was not so significant.27
Ranibizumab is a fab fragment of antibody against VEGF-
A. When ranibizumab was administrated by the subcon-
junctival route in a high-risk murine corneal transplantation
model, it could significantly reduce corneal NV and increase
graft survival.28 The effect of ranibizumab in suture- or burn-
induced animal models of corneal NV has also been studied,
and the results also showed promise for the reduction of
corneal NV by subconjunctival injections23,25,26,29,30 or topical
administration.29,31
Researchers even compared the therapeutic effect between
bevacizumab and ranibizumab in animal models and had
diverse findings from different settings. Some studies
demonstrated no difference between the two agents with
subconjunctival injection,21 whereas others showed relatively
less NV,23,25,26 shorter blood vessels,23,25 lower corneal
opacity score,25 and lower degree of inflammation26 in the
groups treated with bevacizumab compared to those treated
with ranibizumab. However, a small, prospective, open-
labeled, nonrandomized clinical study showed that ranibizu-
mab was superior to bevacizumab in the onset of action and
degree of efficacy when administrated by the topical route.32
Such different outcomes might be related to the difference
between these two antibodies in their molecular sizes and the
ability to penetrate the cornea. By contrast, another new anti-
VEGF-A antibody, called FD006, with even higher binding
326 C.-C. Hsu et al. / Journal of the Chinese Medical Association 78 (2015) 323e330affinity to VEGF than bevacizumab, was developed. In an
alkali-induced model, FD006 was a slightly more effective in
reducing corneal NV, compared to bevacizumab.333.3. Soluble or modified VEGF receptorsSome researchers have pointed out that the expression of
soluble VEGF receptors by alternative splicing or proteolytic
shedding is a natural mechanism to inhibit hemangiogenesis/
lymphangiogenesis and maintain avascularity of the
cornea.34e38 Soluble VEGF receptors can block the effect of
VEGF ligand by VEGF trapping and preventing their binding
to membrane-bound VEGF receptors.
The soluble truncated form of VEGFR-1, called fms-like
tyrosine kinase (sFlt-1, sVEGFR-1), has high affinity to
VEGF-A and is essential to maintain corneal avascularity
during development.34 In a previous study, strongly
expressed sVEGFR-1 in epithelium was found in human
corneal tissues harvested from residual corneal graft, but it
was weakly expressed in the stroma, while neovascularized
corneas showed greatly reduced sVEGFR-1 expression.35
Similarly, VEGFR-2 also has its soluble form (sVEGFR-
2). The increased expression of sVEGFR-2 was observed in
a suture-induced model, inhibiting lymphangiogenesis and
enhancing corneal allograft survival by blocking VEGF-C
function.36 However, monomeric sVEGFR-2 could not
inhibit corneal hemangiogenesis mediated by VEGF-A in a
suture-induced model due to its poor affinity to VEGF-A.
Conversely, recombinant dimeric VEGFR-2-Fc, which has
a better affinity to VEGF-A,39e41 could inhibit corneal
hemangiogenesis in the same model.36 Recently, a novel
truncated soluble isoform of VEGFR3 (sVEGFR-3) was also
reported.38 It could bind with VEGF-C and inhibit lym-
phangiogenesis of the cornea. When the cornea was injured
in a suture-induced model, low levels of sVEGFR-3 and
higher levels of VEGFR-3 were observed in the sutured site.
Similarly, when sVEGFR-3 was knocked down by shRNA,
an increased level of free VEGF-C can be observed, fol-
lowed by increased expression of membrane-bound VEGFR-
3 and formation of lymphatic vessels.38 These findings give
us some new ideas for inhibiting hemangiogenesis and
lymphangiogenesis by overexpression of soluble VEGF re-
ceptors via the following two mechanisms: (1) using soluble
VEGF receptors directly or (2) using recombinant fusion
proteins of the soluble VEGF receptors. Singh et al38 tried
to overexpress sVEGFR-3 by intrastromal injection of
plasmid pCMV.sVEGFR-3 in a suture-induced model and a
penetrating keratoplasty model. Encouragingly, they found
that this method could decrease 58% of the lymphatic area
and 31% of the blood vessel area in the sutured cornea
model, and also increase the survival rate by 40% in the
corneal transplant model. In addition, soluble VEGFR-3 was
further proved, from their immunoprecipitation results, to
suppress hemangiogenesis by blocking VEGF-C-induced
VEGFR-2 phosphorylation.
Employing nanotechnology, Iriyama et al42 used poly(-
ethylene glycol) (PEG)-block-polycation, carryingethylenediamine units in the side chains {PEG-b-P
[Asp(DET)]}, to form polyplex micelles containing sVEGFR-
1 (sFlt-1) plasmid. By subconjunctival injection of these
nanoparticles, the prolonged gene expression of sFlt-1
significantly reduced corneal NV in a suture-induced corneal
model. Another study tested the effect of VEGFR-1 morpho-
lino in a keratoplasty model through subconjunctival injection.
The investigators also found that VEGFR-1 morpholino
decreased angiogenesis/lymphangiogenesis and increased
graft survival.43
A new recombinant fusion protein, named aflibercept [or
VEGF-Trap(R1R2)], has also been developed recently for anti-
angiogenic therapy. Aflibercept recombinant fusion protein
has two main components; the VEGF-binding portions from
the extracellular domains of human VEGF receptors 1 and 2
are further fused to the Fc portion of human immunoglobulin 1
to form the antibody. This antibody has the ability to bind
VEGF-A, VEGF-B, and placental growth factor, so as to
inhibit the original signaling pathway. Oliveira et al44 tested
the effect of intraperitoneal injection of VEGF-Trap(R1R2) in a
bFGF-induced mouse model of corneal NV and found that this
method could reduce corneal NV significantly. Similarly,
Bachmann et al45 tested the effect of intraperitoneal injection
of VEGF-Trap after penetrating keratoplasty in a mouse model
and found reduced corneal revascularization with better graft
survival.
There still exists another concept for blocking VEGF by
using VEGFR intraceptor. KDEL is a quadripeptide retention
signal (LyseAspeGlueLeu) that binds to endoplasmic re-
ticulum retention receptors. It can prevent the secretion of
proteins that are coupled to KDEL.46 When domains 2 and 3
of VEGFR-1 are coupled to KDEL, the recombinant
construct can bind VEGF intracellularly and block the
function of VEGF. When domain 4 is also coupled to KDEL,
the recombinant construct can even be dimerized with
VEGFR-2.47 Two types of VEGFR intraceptors, Flt23k
(coupling domains 2e3 of Flt with KDEL) and Flt24k
(coupling domains 2e4 of Flt with KDEL), have been used as
therapeutic agents. Singh et al48 tested the effect of gene
therapy by intrastromal injection of pCMV.Flt23K or
pCMV.Flt24K. They found pCMV.Flt23K and pCMV.Flt24K
injections could sequester hypoxia-induced VEGF and reduce
alkali-induced VEGF elevation, leucocyte infiltration, and
corneal NV. They also found that Flt24K could bind VEGFR-
2 in their in vitro study.47 Furthermore, Jani et al46 investi-
gated the effect of intrastromal injection of albumin nano-
particles encapsulating pCMV.Flt23K 3 weeks “prior to”
corneal injury in an alkali-induced model. They found that
Flt23K could be expressed for a much longer time by
nanoparticles encapsulating plasmids (5 weeks) than by
naked plasmids (8 days). This result validated that albumin
nanoparticles could prolong the expression of therapeutic
plasmids. The effect of Flt23k in the form of poly L-lactide-
co-glycolide nanoparticles was tested by Cho et al.49 They
performed this study in a murine cornea transplant model and
found that subconjunctival injection of Flt23k poly L-lactide-
co-glycolide nanoparticle could reduce NV,
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bined Flt23k nanoparticle and steroid also elevated the 2-
month graft survival rate significantly.3.4. Another VEGF-A antagonistVEGF-A aptamer pegaptanib is a single-strand RNA that
can bind with VEGF-165 to block its effect on angiogenesis or
vessel permeability. Some studies showed that pegaptanib
could also reduce corneal NV in a burn-induced animal model
by subconjunctival injection, but the effect was less than that
of bevacizumab on the area of corneal NV and degree of
inflammation.23,263.5. Pigment epithelium-derived factorPEDF is a glycoprotein with antiangiogenic, anti-
tumorigenic, and neurotrophic functions. PEDF can inhibit
VEGF, FGF, and interlukin-8 (IL-8/CXCL8)-mediated angio-
genesis by reducing endothelial cell migration and inducing
the cells' apoptosis at the same time.50e52 PEDF was also
found to play a critical role in the antiangiogenic effect of
amniotic membrane transplantation.53 Some researchers found
that topical PEDF or PEDF-derived peptides (P5-2 and P5-3
peptides) could downregulate VEGF expression and inhibit
corneal NV in a chemical-induced corneal model.54,55 Some
other researchers used Synthetic Amphiphile INTeraction-18
(SAINT-18) as a vector to deliver plasmid PEDF by subcon-
junctival injection in a bFGF-induced corneal NV model and
inhibited corneal NV successfully.56,573.6. Platelet-derived growth factorPlatelet-derived growth factors (PDGFs) are proteins involved
in cell growth, division, angiogenesis, and tissue remodeling.
Ligands such as PDGF-A and PDGF-B, and receptors such as
PDGFR-a, PDGFR-b can be found in corneal tissue and are
associated with angiogenesis of the cornea.58,59 Some studies
found that intraperitoneal injection of PDGF receptor inhibitor
(AG 1296) resulted in the loss of capillary pericytes and reduc-
tion of vessel density in advanced corneal NV.60,61 In addition,
another study pointed out that topically administered Sunitinib, a
multitargeted receptor tyrosine kinase inhibitor blocking both
PDGF and VEGF, could reduce corneal NVmore effectively in a
suture-induced model than bevacizumab.623.7. AngiostatinAngiostatin is an endogenous angiogenesis inhibitor
cleaved from plasminogen. Angiostatin can bind with many
surface proteins in vascular endothelial cells and inhibit their
migration, as well as tubule formation.63,64 Angiostatin is also
produced in the cornea. Its depletion through utilization of
artificial antiangiostatin antibodies could increase corneal NV
in an animal excimer laser keratectomy model.65 With the
implantation of an angiostatin pump, corneal NV was also
reduced in an alkali-induced model.663.8. Hypoxia-inducible factorsIn hypoxia-induced NV, hypoxia-inducible factor 1a (HIF-
1a) can bind to the promoter of VEGF gene and activate the
transcription of VEGF. Therefore, Chen et al67 designed a
recombinant vector, named HIF-1a RNAi-A, to express HIF-
1a-specific shRNA. They tested the effect of shRNA by sub-
conjunctival injection in a contact-lens-wearing-with-
tarsorrhaphy-induced corneal NV model and successfully
inhibited corneal NV by reducing the expression of VEGF,
metalloproteinase (MMP)-2/9, and IL-1b.3.9. 12-Hydroxyeicosatrienoic acidCorneal inflammation or hypoxia-induced angiogenesis is
related to 12-hydroxyeicosatrienoic acid, an inflammatory and
angiogenic eicosanoid. This acid is metabolized by cyto-
chrome P450 mono-oxygenase (CYP), and its elevated
expression with prominent activity could be observed in a
contact lens-induced hypoxia model.68e70 Seta et al71 showed
that siRNA targeting at CYP4B1 could inhibit not only the
level of 12-hydroxyeicosatrienoic acid, but also the expression
of VEGF, a reduced corneal NV, in a suture-induced model
through subconjunctival injection.3.10. Vascular adhesion proteinVascular adhesive protein-1/semicarbazide-sensitive amine
oxidase (VAP-1/SSAO) is involved in the adhesion of lympho-
cytes to endothelial cells and is thought to be related to corneal
NV.72 Murine corneal micropocket assay showed that the VAP-1
inhibitor, UeV002, reduced the IL-1b-induced M2 macrophage
infiltration and lymphangiogenesis/hemangiogenesis in the
cornea, but failed in the VEGF-A-induced lymphangiogenesis/
hemangiogenesis.73 Another study showed that corneal VAP-1/
SSAO activity rose after suture stimulation in a rabbit suture-
induced corneal model. VAP-1/SSAO activity could be reduced
by eye drops containing VAP-1/SSAO inhibitor LJP1207, but not
by bevacizumab alone.However, LJP 1207 treatment alone could
not significantly reduce corneal NV.743.11. DecorinDecorin is a small leucine-rich proteoglycan that can sup-
press endothelial migration and angiogenesis. Its deficiency
led to impaired angiogenesis in injured murine cornea.75 Some
evidence showed that membrane type 1-matrix metal-
loproteinase (MT1-MMP) was upregulated in bFGF-induced
corneal micropocket assay, in which decorin was cleaved by
MT-1-MMP in a time- and concentration-dependent manner.76
Mohan et al77 further tested the effect of targeted decorin gene
therapy by topical application of AAV5-dcn vector onto the
de-epithelial stroma in micropocket corneal NV assay. They
found that decorin gene therapy could significantly suppress
corneal NV by downregulating VEGF, macrophage chemo-
attractant protein (MCP1), and angiopoietin, and upregulating
PEDF at the same time.
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regulator of angiogenesis. Zhou et al78 tried subconjunctival
injection of a recombinant adenovirus encoding human
vasohibin-1 in an alkali-induced mouse model, revealing
downregulation of VEGF-R2-expression combined with sig-
nificant reduction of corneal NV.3.13. Cannabinoid receptor CB1Cannabinoid receptor subtype 1 is a highly expressed re-
ceptor in the central nervous system, and can also be found in
ciliary epithelium, corneal epithelium, the endothelium of
human anterior segment, and retina.79 It can be activated by
endocannabinoids and is a potential target for anti-
inflammation or antiangiogenesis. Pisanti et al80 used selec-
tive CB1 antagonist rimonabant in a bFGF-stimulated rabbit
corneal angiogenesis assay and reported a remarkably reduced
angiogenesis by using rimonabant.
4. Immunosuppressant4.1. SteroidSteroid is the most widely used immunosuppressant clini-
cally. It is also frequently used in ocular disorders to reduce
ocular inflammation due to infection, immune response, or
ocular surgery. Steroid was found to reduce the development
of corneal NV by reducing inflammatory cell recruitment and
the level of cytokine, but it could not effectively reduce pre-
existing mature corneal NV. An alkali-induced corneal
model showed that subconjunctival injection of dexametha-
sone reduced the intensity of inflammation and area of corneal
NV.81 Another study, of a murine suture-induced corneal
model, revealed that topical steroids (dexamethasone, pred-
nisolone, and fluorometholone) can reduce both hemangio-
genesis and lymphangiogenesis to different degrees.82
Some studies also looked into the relationship between the
effect and timing of steroid administration. In a study of IL-
1b-induced corneal micropocket assay, corneal NV could be
reduced by topical dexamethasone when it was used within 4
days after IL-1b implantation.83 Another study using a murine
keratoplasty model found that combined pre- and post-
treatment of subconjunctival glucocorticoid led to less
hemangiogenesis and lymphangiogenesis, compared with the
result of using post-treatment only.84 By contrast, both pre-
and post-treatment of glucocorticoid showed similar effects of
reducing hemangiogenesis and lymphangiogenesis in a murine
suture corneal model.844.2. Rapamycin and cyclosporine ASome studies tested the effect of other immunosuppres-
sants, such as rapamycin and cyclosporine A, in the treatment
of corneal NV. Topical rapamycin was found to be effective in
reducing angiogenesis and necrosis in a model of HSV-1stromal keratitis.85 Another study showed that using 0.5%
rapamycin eye drop of nanometer vector twice per day alone
or combined with polylactic acid wafers of cyclosporine A in
the anterior chamber could reduce inflammatory cellular
infiltrate and the expression of VEGF gene in a rabbit corneal
allograft model.864.3. Thalidomide analogue CC-3052Thalidomide is an immunomodulatory and anti-
inflammatory agent, but it also has teratogenic and neuro-
toxic effects. Thalidomide can inhibit tumor necrosis factor-
alpha (TNF-a) and FGF-2-medicated angiogenesis and act as
a potential inhibitor of angiogenesis. Lee and Chung87 used a
water-soluble analog of thalidomide, CC-3052, as a new po-
tential medication for corneal NV in a suture-induced model.
They found that topical administration of CC-3052 twice-a-
day reduced corneal NV.
In conclusion, corneal angiogenesis takes place by upre-
gulation of angiogenic factors and/or downregulation of anti-
angiogenic factors. In order to prevent or treat corneal NV,
these angiogenesis-related factors can be manipulated by
means of monoclonal antibodies, modified receptors, aptam-
ers, and inhibitors of possible angiogenesis pathways. We have
summarized these recently discovered therapeutic targets in
this review article. However, further studies are still required
to confirm the efficacy and safety of these novel therapies in
clinical practice.References
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